Prevalence of 13 autoantibodies and of the 16/6 and related pathogenic idiotypes in 465 patients with systemic lupus erythematosus and their relationship with disease activity
Restricted accessResearch articleFirst published online June, 1997
Prevalence of 13 autoantibodies and of the 16/6 and related pathogenic idiotypes in 465 patients with systemic lupus erythematosus and their relationship with disease activity
With a cross sectional study of 465 consecutive systemic lupus erythematosus (SLE) patients tested for 13 autoantibodies (Aab) and two idiotypes we determined the prevalence of Aab according to disease activity, both general and at particular organ systems.
Seventy seven percent of SLE sera had at least one Aab and 56% had it at high titres. Pathogenic idiotypes had a prevalence of less than 10% and 166 sera had Aab to 5 or more antigens and 9 sera had Aab against all 13 antigens tested.
Patients with active disease had increased prevalence of Aab to DNP, ssDNA, ENA, mitochondria and histones when considered at 5 s.d. above the mean of normal controls. The higher positivity of Aab in patients with active disease was confirmed in logistic regression analysis adjusted by age, disease duration, and intensity of treatment.
A trend was observed of increased prevalence and titres of Aab from inactive disease without treatment, to inactive disease but still being treated, to active disease. Only 22% of patients with active disease had no Aab and the higher the number of Aab the higher the frequency of active disease.
Patients with active arthritis, and to a lesser degree those with active mucocutaneous involvement, had higher prevalence and titres of most autoantibodies than patients with disease activity at other organ systems. Active renal disease associated only with anti-dsDNA, whereas active CNS disease associated with anti-mitochondrial Aab.
Our findings support the vision of SLE as an immune dysregulation leading to polyclonal B cell .. activation with resulting production of multiple Aab. Their profiles seem influenced by genetical, hormonal and environmental factors and, in turn, they contribute to the clinical picture in each patient. Disease activity influences the presence of some, but not all, Aab and some of them may remain present in some patients, even in remission.
Shoenfeld Y. et al. The role of human anti-DNA idiotype 16/6 in autoimmunity. Clin Immunol Immunopathol1989; 51: 313-325.
2.
Bakimer R. et al. The frequency of a common anti-DNA antibody idiotype (16/6) in different populations of patients with systemic lupus erythematosus. J Rheumatol1991; 18: 1035-1037.
3.
Gripenberg M. , Teppo AM, Friman C.Antibodies to Sm and SS-A demonstrated by enzyme immunoassay. Correlation to clinical manifestations and disease activity in patients with systemic lupus erythematosus. Rheumatol Int1991; 11: 209-213.
4.
Borg A. et al. Changes in levels of antibodies against the 70 kDa and polypeptides of the U1RNP complex in relation to exacerbations of systemic lupus erythematosus . J Rheumatol1991; 18: 363-367.
5.
Muller S. et al. Longitudinal analysis of antibodies to histones, Sm-D peptides and ubiquitin in the serum of patients with systemic lupus erythematosus, rheumatoid arthritis and tuberculosis. Clin Exp Rheumatol1990; 8: 445-453.
6.
Purcell SM, Lieu TS, Davis BM, Sontheimer RDRelationship between circulating anti-Ro/SSA antibody (a-Ro) levels and skin disease activity in subacute cutaneous lupus erythematosus (SCLE) . Arthritis Rheum1985; 28: S76 (abstract D4).
7.
Blanco F., Kalsi J., Isenberg DAAnalysis of antibodies to RNA in patients with systemic lupus erythematosus and other autoimmune rheumatic diseases. Clin Exp Immunol1991; 86: 66-70.
8.
Simmons-O'Brien E. et al. One hundred anti-Ro (SS-A) antibody positive patients: a 10-year follow-up. Medicine1995; 74: 109-130.
9.
Thompson D., Juby A., Davis P.The clinical significance of autoantibody profiles in patients with systemic lupus erythematosus. Lupus1993; 2: 15-19.
10.
Skinner RP, Maddison PJAnalysis of polyethylene glycol precipitates from SLE sera: antibody enrichment in association with disease activity. Clin Exp Rheumatol1990; 8: 553-560.
11.
Smolen JS, Hassfeld W., Graninger W., Steiner G.Antibodies to antinuclear subsets in systemic lupus erythematosus and rheumatoid arthritis. Clin Exp Rheumatol1990; 8: 41-44.
12.
Pérez-Vázquez ME, Cabiedes J., Cabral AR, Alarcón-Segovia D.Decrease in serum antiphospholipid antibody levels upon development of nephrotic syndrome in patients with systemic lupus erythematosus: relationship to urinary loss of IgG and other factors . Am J Med1992; 92: 357-362.
13.
Nossent JC et al. Relation between serological data at the time of biopsy and renal histology in lupus nephritis. Rheumatol Int1991; 11: 77-82.
14.
Hietarinta M., Viander M., Toivanen A., Lassila O.Clinical significance of autoantibodies in systemic lupus erythematosus. Br J Rheumatol1994; 33: 1202-1203.
15.
Shoenfeld Y. , Mozes E.Pathogenic anti-DNA idiotype (16/6 Id) in systemic lupus erythematosus. Rheumatol Int1991; 11: 91-93.
16.
Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271-1277.
17.
Drenkard C. et al. Remission of systemic lupus erythematosus . Medicine1996; 75: 88-98.
18.
Shoenfeld Y. et al. Polyspecificity of monoclonal lupus autoantibodies by human hybridoma. N Engl J Med1983; 308: 414-420.
19.
Shoenfeld Y. , El-Roeiy A., Ben-Yehuda O., Pick ALDetection of antihistone activity in the sera of patients with monoclonal gammopathies. Clin Immunol Immunopathol1987; 42: 250-258.
20.
Shoenfeld Y. et al. Monoclonal anti-DNA autoantibodies react with Mycobacterium tuberculosis. Clin Exp Immunol1986; 66: 255-261.
21.
Isenberg DA , Shoenfeld Y., Schwartz RSMultiple serologic reactions and their relationship to clinical activity in systemic lupus erythematosus . Arthritis Rheum1984; 27: 132-138.
22.
Firer M., Shoenfeld Y., Isenberg DA, Slor H.The use of ELISA for the measurement of autoantibodies to nuclear antigens: comparison with other methodologies. Isr J Med Sci1988; 24: 747-751.
23.
Zurgil N. et al. Antimithochondrial (pyruvate dehydrogenase) autoantibodies in autoimmune rheumatic diseases. J Clin Immunol1992; 12: 201-209.
24.
Isenberg D. et al. Anti-DNA antibody idiotypes in SLE. Lancet1984; ii: 417-421.
25.
Shoenfeld Y. , Mozes E.Pathogenic idiotypes of autoantibodies and autoimmunity: a lesson from a new syndrome of experimental SLE. FASEB J1990; 4: 2646-2651.
26.
Cupples LA et al. Multiple testing of hypotheses in comparing two groups. Ann Int Med1984; 100: 122-129.
27.
Hosmer DW, Lemeshow S.Applied Logistic Regression. John Wiley and Sons : New York, 1989, p 25.
28.
Kleinbaum DG , Kupper LLApplied Regression Analysis and Other Multivariable Methods. Duxbury Press: Massachusetts , 1978 , p. 414.
29.
Guzmán J. et al. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol1992; 19: 1551-1558.
30.
Arce-Salinas A., Cardiel MH, Guzmán J., Alcocer-Varela J.Validity of retrospective disease activity assessment in systemic lupus erythematosus . J Rheumatol1996; 23: 846-849.
Froelich CJ , Wallman J., Skosey JL, Teodorescu M.Clinical value of an integrated ELISA system for the detection of 6 autoantibodies (ssDNA, dsDNA, Sm, RNP/Sm, SSA, and SSB). J Rheumatol1990; 17: 192-200.
33.
Harley J. et al. A model for disease heterogeneity in systemic lupus erythematosus. Relationships between histocompatibility antigens, autoantibodies, and lymphopenia or renal disease. Arthritis Rheum1989; 32: 826-836.
34.
Swaak Ajg, Huysen V., Nossent JC, Smeenk Rjt.Antinuclear antibody profiles in relation to specific disease manifestations of systemic lupus erythematosus. Clin Rheumatol1990; 9: 82-95.
35.
Meroni PL et al. Anti-mitochondrial type M5 and anti-cardiolipin antibodies in autoimmune disorders: studies on their association and cross-reactivity. Clin Exp Immunol1987; 67: 484-491.
36.
Drenkard C., Sánchez-Guerrero J., Alarcón-Segovia D.Fall in antiphospholipid antibody at the time of thromboocclusive episodes in systemic lupus erythematosus. J Rheumatol1989; 16: 614-617.
37.
Cabiedes J. , Cabral AR, Alarcón-Segovia D.Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-β2-glycoprotein-1 than with antiphospholipid antibodies. J Rheumatol1995 ; 22: 1899-1906.
38.
Laperche S. et al. Association of antimitochondrial antibodies type 5 and anti-β2 glycoprotein 1 antibodies in the antiphospholipid syndrome . J Rheumatol1994; 21: 1678-1683.
39.
Delezé M., Oria C., Alarcón-Segovia D.Occurrence of both hemolytic anemia and thrombocytopenic purpura (Evans' syndrome) in systemic lupus erythematosus. Relationship to antiphospholipid antibodies . J Rheumatol1989; 16: 614-617.
40.
Hochberg MC et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine1985; 64: 285-295.
41.
García-de la Torre I., Sánchez-Guerrero S., Salmón-de la Torre G., Hemández-Vázquez L.Prevalence of anti-SSA (Ro) antibodies in a Mexican population of patients with various systemic rheumatic diseases. J Rheumatol1987; 14: 479-481.
42.
Gripenberg M., Teppo AM, Friman C.Antibodies to Sm and SS-A demonstrated by enzyme immunoassay. Correlation to clinical manifestations and disease activity in patients with systemic lupus erythematosus. Rheumatol Int1991; 11: 209-213.
43.
Alarcón-Segovia D.The pathogenesis of immune dysregulation in systemic lupus erythematosus. A troika. J Rheumatol1984; 11: 588-590.
44.
Llorente L. et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus . J Exp Med1995; 181: 839-844.
